Q1 2024 · 13F-HR
BVF INC/ILholdings as filed
Filed 2024-05-15 · accession 0000921895-24-001219
$3.64B
Reported value
62
Positions
2024-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $1.09B | 30.0% | 21,751,284 | Common | SHARED |
| 501575104 | KYMR | KYMERA THERAPEUTICS INC | $207.5M | 5.70% | 5,161,801 | Common | SHARED |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $192.8M | 5.30% | 5,981,212 | Common | SHARED |
| 35104E100 | FDMT | 4D MOLECULAR THERAPEUTICS IN | $125.0M | 3.44% | 3,922,413 | Common | SHARED |
| G3855L106 | GHRS | GH RESEARCH PLC | $110.9M | 3.05% | 10,400,158 | Common | SHARED |
| 47103J105 | JANX | JANUX THERAPEUTICS INC | $109.9M | 3.02% | 2,919,818 | Common | SHARED |
| 604749101 | MIRM | MIRUM PHARMACEUTICALS INC | $109.8M | 3.02% | 4,370,024 | Common | SHARED |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $108.7M | 2.99% | 3,755,990 | Common | SHARED |
| 462222100 | IONS | IONIS PHARMACEUTICALS INC | $105.3M | 2.89% | 2,428,613 | Common | SHARED |
| 68062P106 | OLMA | OLEMA PHARMACEUTICALS INC | $103.4M | 2.84% | 9,135,893 | Common | SHARED |
| 50127T109 | KURA | KURA ONCOLOGY INC | $102.1M | 2.81% | 4,786,293 | Common | SHARED |
| 98419J206 | XOMA | XOMA CORP DEL | $87.4M | 2.40% | 3,633,743 | Common | SHARED |
| 156944100 | CGON | CG ONCOLOGY INC | $82.7M | 2.27% | 1,884,191 | Common | SHARED |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $76.4M | 2.10% | 4,661,194 | Common | SHARED |
| 29668H708 | EPIEUR | ESSA PHARMA INC | $74.3M | 2.04% | 8,748,629 | Common | SHARED |
| 98985Y108 | ZYME | ZYMEWORKS INC | $61.8M | 1.70% | 5,870,000 | Common | SHARED |
| 36315X101 | LKFT | GALAPAGOS NV | $60.0M | 1.65% | 1,863,809 | Common | SHARED |
| 230031106 | CGEM | CULLINAN ONCOLOGY INC | $54.5M | 1.50% | 3,196,701 | Common | SHARED |
| N5749R100 | 2GH | MERUS N V | $52.8M | 1.45% | 1,172,249 | Common | SHARED |
| 45166A102 | IDYA | IDEAYA BIOSCIENCES INC | $51.0M | 1.40% | 1,162,306 | Common | SHARED |
| 03589W102 | ANNX | ANNEXON INC | $50.2M | 1.38% | 7,000,000 | Common | SHARED |
| 760273102 | RPTX | REPARE THERAPEUTICS INC | $48.7M | 1.34% | 10,333,600 | Common | SHARED |
| 282559103 | ETNBGBP | 89BIO INC | $47.1M | 1.30% | 4,047,354 | Common | SHARED |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $44.6M | 1.23% | 1,875,000 | Common | SHARED |
| H00263105 | ACIU | AC IMMUNE SA | $43.1M | 1.19% | 14,571,236 | Common | SHARED |
| 88427A107 | — | THIRD HARMONIC BIO INC | $41.2M | 1.13% | 4,365,933 | Common | SHARED |
| 29286M105 | — | ENGENE HOLDINGS INC | $38.2M | 1.05% | 2,251,037 | Common | SHARED |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $36.0M | 0.99% | 1,521,948 | Common | SHARED |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $34.8M | 0.96% | 812,988 | Common | SHARED |
| G76279101 | ROIV | ROIVANT SCIENCES LTD | $28.9M | 0.79% | 2,742,409 | Common | SHARED |
| 38000Q102 | GLYCEUR | GLYCOMIMETICS INC | $28.6M | 0.79% | 9,544,262 | Common | SHARED |
| 89854M101 | TCRX | TSCAN THERAPEUTICS INC | $23.7M | 0.65% | 2,989,474 | Common | SHARED |
| 01671P100 | ALLKGUSD | ALLAKOS INC | $20.9M | 0.57% | 16,552,417 | Common | SHARED |
| 92337C203 | VSTM | VERASTEM INC | $19.9M | 0.55% | 1,685,219 | Common | SHARED |
| 13124Q106 | — | CALLIDITAS THERAPEUTICS AB | $16.2M | 0.45% | 750,000 | Common | SHARED |
| 23284F105 | CTMX | CYTOMX THERAPEUTICS INC | $14.4M | 0.40% | 6,595,801 | Common | SHARED |
| 28623U101 | — | ELEVATION ONCOLOGY INC | $11.9M | 0.33% | 2,312,200 | Common | SHARED |
| 690469101 | OVID | OVID THERAPEUTICS INC | $11.8M | 0.32% | 3,853,818 | Common | SHARED |
| 4525EP101 | VTLUSD | IMMUNIC INC | $11.8M | 0.32% | 8,902,972 | Common | SHARED |
| 92840H400 | VTGN | VISTAGEN THERAPEUTICS INC | $10.6M | 0.29% | 2,000,000 | Common | SHARED |
| 28617K101 | ELDN | ELEDON PHARMACEUTICALS INC | $8.9M | 0.25% | 4,326,710 | Common | SHARED |
| 92539P101 | — | VERVE THERAPEUTICS INC | $8.6M | 0.24% | 650,000 | Common | SHARED |
| 45175G108 | — | IKENA ONCOLOGY INC | $6.8M | 0.19% | 4,769,164 | Common | SHARED |
| 171757107 | — | CIDARA THERAPEUTICS INC | $6.3M | 0.17% | 6,861,127 | Common | SHARED |
| 92673K108 | VIGL | VIGIL NEUROSCIENCE INC | $6.2M | 0.17% | 1,813,633 | Common | SHARED |
| 24661P807 | DCTH | DELCATH SYS INC | $5.7M | 0.16% | 1,202,067 | Common | SHARED |
| 90466Y103 | — | UNICYCIVE THERAPEUTICS INC | $5.0M | 0.14% | 3,611,601 | Common | SHARED |
| 29286M113 | — | ENGENE HOLDINGS INC | $4.9M | 0.14% | 945,402 | Common | SHARED |
| 78397T202 | SABS | SAB BIOTHERAPEUTICS INC | $4.2M | 0.11% | 917,826 | Common | SHARED |
| 528872302 | LXRX | LEXICON PHARMACEUTICALS INC | $4.0M | 0.11% | 1,686,924 | Common | SHARED |
| 037326105 | ANTX | AN2 THERAPEUTICS INC | $4.0M | 0.11% | 1,239,470 | Common | SHARED |
| 50107A104 | KRON1USD | KRONOS BIO INC | $3.8M | 0.10% | 2,905,043 | Common | SHARED |
| 720795103 | PIRSEUR | PIERIS PHARMACEUTICALS INC | $3.8M | 0.10% | 20,609,863 | Common | SHARED |
| 92765F108 | RYI | VIRACTA THERAPEUTICS INC | $3.7M | 0.10% | 3,614,662 | Common | SHARED |
| 46124U107 | IVA | INVENTIVA SA | $2.5M | 0.07% | 686,040 | Common | SHARED |
| 34962G109 | TOCAEUR | FORTE BIOSCIENCES INC | $2.1M | 0.06% | 2,982,105 | Common | SHARED |
| 60853G106 | MOLN | MOLECULAR PARTNERS AG | $1.7M | 0.05% | 443,221 | Common | SHARED |
| 608550208 | MTEMEUR | MOLECULAR TEMPLATES INC | $1.2M | 0.03% | 522,238 | Common | SHARED |
| H57830103 | — | NLS PHARMACEUTICS LTD | $1.0M | 0.03% | 5,747,126 | Common | SHARED |
| 04522R200 | — | ASLAN PHARMACEUTICALS LTD | $645,959 | 0.02% | 1,049,999 | Common | SHARED |
| 221015100 | CRVS | CORVUS PHARMACEUTICALS INC | $643,303 | 0.02% | 361,406 | Common | SHARED |
| 76200L309 | RZLT | REZOLUTE INC | $486,578 | 0.01% | 190,815 | Common | SHARED |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.